Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

Rhea-AI Summary

Amneal (NASDAQ: AMRX) announced U.S. FDA approval of its cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials and approved as the generic equivalent of RESTASIS.

The company says the product will launch in Q1 2026. The approval highlights Amneal’s sterile manufacturing capabilities and expansion in complex ophthalmic therapies. IQVIA U.S. annual sales for this product format were ~$2.0 billion for the 12 months ended September 2025. The drug is indicated to increase tear production for dry eye due to ocular inflammation; the most common adverse reaction was ocular burning.

Positive

• FDA approval secured for cyclosporine ophthalmic emulsion 0.05%
• Launch planned Q1 2026 for U.S. market entry
• $2.0B IQVIA U.S. annual sales for this product format (12 months ended Sep 2025)
• Sterile, preservative-free single-use vials align with preferred ophthalmic delivery

Negative

• Most common adverse reaction: ocular burning
• Increased tear production not observed in patients using topical anti-inflammatory drugs or punctal plugs

News Market Reaction – AMRX

-2.52%

-2.52% Session close to close

In the Dec 2 session, AMRX declined 2.52%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds another FDA-approved complex ophthalmic product to Amneal’s portfolio, target...

Analysis

This announcement adds another FDA-approved complex ophthalmic product to Amneal’s portfolio, targeting dry eye patients with a generic to a reference market of about $2.0 billion in U.S. annual sales. It follows several recent approvals across injectables and respiratory therapies, reinforcing the company’s sterile manufacturing capabilities. Key factors to watch include the planned Q1 2026 launch, competitive dynamics in cyclosporine, and how new products contribute to overall revenue mix.

Key Figures

Dose strength: 0.05% Reference sales: $2.0 billion Launch timing: Q1 2026

3 metrics

Dose strength 0.05% Cyclosporine ophthalmic emulsion concentration

Reference sales $2.0 billion IQVIA U.S. annual sales, 12 months ended September 2025

Launch timing Q1 2026 Planned U.S. launch for cyclosporine ophthalmic emulsion 0.05%

Historical Context

5 past events · Latest: Dec 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 09	FDA approval	Positive	+2.0%	FDA approval of epinephrine injection vials for hospital use.
Dec 05	Clinical data	Positive	+2.4%	Positive interim Phase 4 ELEVATE-PD results for CREXONT in Parkinson’s.
Dec 02	Investor conferences	Neutral	-2.5%	Announcement of participation in upcoming healthcare investor conferences.
Dec 02	FDA approval	Positive	-2.5%	FDA approval of generic albuterol sulfate inhalation aerosol.
Dec 01	FDA approval	Positive	-2.5%	FDA approval of cyclosporine ophthalmic emulsion 0.05% generic to Restasis.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent FDA approvals and clinical data often led to positive moves, but several FDA approvals, including this one, saw negative reactions, indicating mixed follow-through.

Recent Company History

Over the past six months, Amneal has reported multiple U.S. FDA approvals and a positive Phase 4 Parkinson’s trial, alongside routine investor conference updates. Notable wins include respiratory and ophthalmic generics with IQVIA sales references up to $2.0 billion annually. Price reactions were positive for some approvals and clinical data but negative for others, showing that even strong regulatory milestones have not consistently translated into upside, a context relevant for this latest cyclosporine approval.

Key Terms

immunomodulator, ocular inflammation, punctal plugs, ophthalmic

4 terms

immunomodulator medical

"Cyclosporine ophthalmic emulsion 0.05% is a topical immunomodulator indicated"

An immunomodulator is a medicine or therapy that changes how the immune system behaves—either boosting its ability to fight infections and cancer or calming it to reduce harmful inflammation. Investors watch these products because their success in clinical trials, safety and side-effect profiles, and regulatory approvals can open large markets or limit sales; think of them as tools that tweak the body’s defense system, with outcomes that strongly affect a drug maker’s future revenue and stock value.

ocular inflammation medical

"suppressed due to ocular inflammation associated with dry eye syndrome."

Ocular inflammation is swelling or irritation inside the eye caused by infection, an immune reaction, injury, or other triggers, and can affect structures such as the iris, retina or surrounding tissues. For investors it matters because it drives demand for therapies, influences clinical trial outcomes and regulatory decisions, and can change a company’s revenue and cost outlook—like spotting a leak that signals the need for repairs and potential expense or opportunity.

punctal plugs medical

"Increased tear production was not seen in patients ... using punctal plugs."

Punctal plugs are small, biocompatible devices inserted into the tear ducts at the corner of the eyelids to slow or stop tear drainage, helping the eye retain moisture much like putting a stopper in a sink keeps water from flowing away. Investors care because these single-use or long-lasting medical devices represent a product category with clear clinical purpose, regulatory pathways and reimbursement considerations, so sales, approvals or new designs can directly affect a company’s revenue and growth prospects.

ophthalmic medical

"expansion within complex ophthalmic therapies; Launch expected in Q1 2026"

Relating to the eye and its care, including medicines, drops, diagnostic tools and surgical devices used to prevent, diagnose or treat eye conditions. Investors care because ophthalmic products form a distinct market with specialized safety approvals, manufacturing needs and payer coverage, so success or failure in this area can drive steady revenue or costly setbacks—think of it as a niche, high‑safety consumer product line for vision health.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 
  

BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generic equivalent of RESTASIS^® (cyclosporine ophthalmic emulsion) 0.05%, a registered trademark of Allergan, an AbbVie company.

“Dry eye disease affects millions of adults in the United States and can significantly impact their quality of life,” said Dr. Srinivas Kone, Senior Vice President, Chief Scientific Officer – Affordable Medicines. “We are proud to bring another difficult-to-manufacture ophthalmic product to market, reinforcing Amneal’s strong execution in complex formulations and our expanding leadership in ophthalmology within the Affordable Medicines segment. Cyclosporine joins a series of recent approvals across inhalation, injectable, and ophthalmic categories, underscoring Amneal’s strong execution in high-quality sterile manufacturing.”

Cyclosporine ophthalmic emulsion 0.05% is a topical immunomodulator indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with dry eye syndrome. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

The most common adverse reaction associated with cyclosporine ophthalmic emulsion 0.05% was ocular burning. Please see full Prescribing Information here.

According to IQVIA^® U.S. annual sales for cyclosporine ophthalmic emulsion 0.05% in sterile, preservative-free single-use vials for the 12 months ended September 2025 were approximately $2.0 billion.

Note: RESTASIS^® is a registered trademark of Allergan, an AbbVie company.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 290 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn.

Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com

Media Contact
Brandon Skop
Sr. Director, Corporate Communications
brandon.skop@amneal.com

FAQ

What did Amneal (AMRX) announce about cyclosporine ophthalmic emulsion on December 1, 2025?

Amneal announced U.S. FDA approval of cyclosporine ophthalmic emulsion 0.05% as a generic equivalent to RESTASIS, with a planned Q1 2026 launch.

How large is the U.S. market for cyclosporine ophthalmic emulsion 0.05% in single-use vials?

IQVIA reported approximately $2.0 billion in U.S. annual sales for this product format for the 12 months ended September 2025.

What formulation and packaging does Amneal’s approved cyclosporine use?

The approved product is a sterile, preservative-free ophthalmic emulsion supplied in single-use vials.

When will Amneal (AMRX) launch its cyclosporine ophthalmic emulsion 0.05%?

Amneal expects a U.S. launch in Q1 2026.

What are the main safety notes for Amneal’s cyclosporine ophthalmic emulsion 0.05%?

The most common adverse reaction was ocular burning; increased tear production was not seen in patients using topical anti-inflammatory drugs or punctal plugs.